US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATS Corp.

25.79

+0.58002.30%

Post-market: 25.790.00000.00%16:43 EDT

Volume:112.69K

Turnover:2.89M

Market Cap:2.53B

PE:41.15

High:25.87

Open:25.33

Low:25.17

Close:25.21

Loading ...

Overview Company News Filings

Press Release: aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

OTC Markets Group Welcomes Steel Partners Holdings L.P. to OTCQX

Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases

PureTech Health to Present Promising IPF Trial Results at ATS Conference

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

Australis Oil & Gas Issues New Securities to Boost Market Position

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Celestica Announces First Quarter 2025 Financial Results

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

ICE Bonds Enhances MBS Trading With New RFQ Protocol on ICE TMC Platform

SkyWater Appoints Dr. Percy Gilbert as Senior Vice President of Engineering

Press Release: Securitize Acquires MG Stover's Fund Administration Business to Become the Largest Digital Asset Fund Administrator

ParaZero Launches SafeAir M4 – Its Most Advanced Parachute Recovery System, Now Compatible with DJI Matrice 4

ATS Corporation to Engage with Investors at RBC Capital Markets Conference

ATS to Participate in the RBC Capital Markets Canadian Industrials Conference

AI might be scanning your resume. Here’s what job hunters should know

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Is Now An Opportune Moment To Examine ATS Corporation (TSE:ATS)?

Simply Wall St.

Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATS\",,,,,undefined,":{"symbol":"ATS","market":"US","secType":"STK","nameCN":"ATS Corp.","latestPrice":25.79,"timestamp":1746820800000,"preClose":25.21,"halted":0,"volume":112689,"hourTrading":{"tag":"盘后","latestPrice":25.79,"preClose":25.79,"latestTime":"16:43 EDT","volume":26081,"amount":671895.254712,"timestamp":1746823429747},"delay":0,"floatShares":81570898,"shares":97928315,"eps":0.626793,"marketStatus":"Market Closed","change":0.58,"latestTime":"05-09 16:00:00 EDT","open":25.33,"high":25.87,"low":25.17,"amount":2886126.547959,"amplitude":0.027767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.626793,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":7,"adr":0,"listingDate":1684987200000,"exchange":"NYSE","adjPreClose":25.21,"preHourTrading":{"tag":"盘前","latestPrice":25.21,"preClose":25.21,"latestTime":"05:49 EDT","volume":1,"amount":25.21,"timestamp":1746784194609},"postHourTrading":{"tag":"盘后","latestPrice":25.79,"preClose":25.79,"latestTime":"16:43 EDT","volume":26081,"amount":671895.254712,"timestamp":1746823429747},"volumeRatio":0.9407730956728827,"impliedVol":0.292,"impliedVolPercentile":0.204},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATS\",,,,,undefined,":{"symbol":"ATS","floatShares":81570898,"roa":"3.37%","roe":"5.30%","lyrEps":1.463463,"volumeRatio":0.9407730956728827,"shares":97928315,"dividePrice":0,"high":25.87,"amplitude":0.027767,"preClose":25.21,"low":25.17,"week52Low":20.9,"pbRate":"2.01","psRate":"1.28","week52High":35.415,"institutionHeld":0,"latestPrice":25.79,"eps":0.626793,"divideRate":0,"volume":112689,"delay":0,"ttmEps":0.626793,"open":25.33,"prevYearClose":30.48,"prevWeekClose":25.81,"prevMonthClose":25.16,"prevQuarterClose":24.93,"fiveDayClose":25.81,"twentyDayClose":23.53,"sixtyDayClose":29.25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533240965","title":"Press Release: aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533240965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533240965?lang=en_us&edition=fundamental","pubTime":"2025-05-08 04:01","pubTimestamp":1746648060,"startTime":"0","endTime":"0","summary":"Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025.Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025.SAN DIEGO, May 07, 2025  -- aTyr Pharma, Inc.  , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2025 results and provided a corporate update.\"Throughout the first quarter of 2025 we have maintained strong and steady progress with our clinical program for efzofitimod in interstitial lung disease ,\" said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. \"The program's cornerstone is our Phase 3 EFZO-FIT study in pulmonary sarcoidosis, the most prevalent form of ILD for which no new treatments have been approved in mor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4161","ATS","BK4099","BK4555","ATYR","BK4604","TM","BK4585","BK4588","03160"],"gpt_icon":0},{"id":"2532817970","title":"OTC Markets Group Welcomes Steel Partners Holdings L.P. to OTCQX","url":"https://stock-news.laohu8.com/highlight/detail?id=2532817970","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532817970?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:00","pubTimestamp":1746183600,"startTime":"0","endTime":"0","summary":"NEW YORK, May 02, 2025  -- OTC Markets Group Inc. , operator of regulated markets for trading 12,000 U.S. and international securities, today announced Steel Partners Holdings L.P. , a diversified global holding company, has qualified to trade on the OTCQX Best Market. Steel Partners Holdings LP previously traded on the New York Stock Exchange.Trading on the OTCQX Market offers companies efficient, cost-effective access to the U.S. capital markets. Streamlined market requirements for OTCQX are designed to help companies lower the cost and complexity of being publicly traded, while providing transparent trading for their investors. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.OTC Markets Group Inc.  operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/otc-markets-group-welcomes-steel-110000181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPLP","BK4161","BK4112","OTCM","ATS","BK4206"],"gpt_icon":0},{"id":"2532070899","title":"Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2532070899","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532070899?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:00","pubTimestamp":1746104400,"startTime":"0","endTime":"0","summary":"24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease  and asthma. COPD data from the landmark Phase 3 trials will highlight Dupixent impact on lung function and health-related quality of life across broad populations of patients with type 2 inflammation. Asthma abstracts include late-breaking data on mucus burden and the first presentation of efficacy results from a Phase 2 trial designed to study Dupixent in allergic bronchopulmonary aspergillosis  in patients with asthma. COPD data assess Dupixent impact on lung function and exacerbations in COPD, including patients with or without emphysema Notable abstracts in COPD will highlight new results from the pivotal landmark Phase 3 BOREAS and NOTUS trials, including analyses demonstrating Dupixent reduced exacerbations and improved lung function regardless of whether patients had emphysema. In the pivotal COPD trials, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dupixent-dupilumab-data-presented-ats-130000007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053666078.USD","PT","LU0882574055.USD","BK4166","ATS","LU0289739699.SGD","LU0823416689.USD","LU2362540622.SGD","BK4161","LU2362541273.HKD","LU2237438978.USD","LU0109394709.USD","LU0114720955.EUR","LU2468319806.SGD","LU2362541513.USD","LU1974910355.USD","REGN","LU0320765992.SGD","BK4588","PN","LU2089984988.USD","LU0058720904.USD","LU2023250504.SGD","BK4096","BK4585","BK4139","LU1917777945.USD","LU0889565916.HKD","LU2106854487.HKD"],"gpt_icon":0},{"id":"2532073898","title":"PureTech Health to Present Promising IPF Trial Results at ATS Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2532073898","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532073898?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:03","pubTimestamp":1746097385,"startTime":"0","endTime":"0","summary":"PureTech Health ( ($GB:PRTC) ) has provided an update. PureTech Health announced that it will present results from its Phase 2b ELEVATE IPF trial o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/puretech-health-to-present-promising-ipf-trial-results-at-ats-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/puretech-health-to-present-promising-ipf-trial-results-at-ats-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATS","BK4161"],"gpt_icon":0},{"id":"2532500381","title":"PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2532500381","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532500381?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis . Regulatory and strategic planning underway to advance deupirfenidone into Phase 3 development. The presentation will highlight data from the recently completed Phase 2b ELEVATE IPF trial of deupirfenidone , which demonstrated unprecedented efficacy outcomes in patients living with idiopathic pulmonary fibrosis , including the potential to stabilize lung function decline at 26 weeks while maintaining safety and tolerability.The Phase 2b ELEVATE IPF trial was a global, randomized, double-blind, active- and placebo-controlled, dose-ranging trial designed to evaluate the efficacy, tolerability, safety, and dosing regimen of deupirfenidone  in patients with IPF compared to pl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/puretech-present-results-phase-2b-110000010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","PRTC","SOC","BK4117","BK4213","ATS","LYT","FVC","BK4107","BK4161","BK4108","BK4139"],"gpt_icon":0},{"id":"2532046880","title":"Australis Oil & Gas Issues New Securities to Boost Market Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2532046880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532046880?lang=en_us&edition=fundamental","pubTime":"2025-05-01 11:27","pubTimestamp":1746070071,"startTime":"0","endTime":"0","summary":"The latest update is out from Australis Oil & Gas ( ($AU:ATS) ). Australis Oil & Gas Limited announced the issuance of 17,555,844 fully paid ordina...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/australis-oil-gas-issues-new-securities-to-boost-market-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/australis-oil-gas-issues-new-securities-to-boost-market-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4161","ATS"],"gpt_icon":0},{"id":"2530472503","title":"Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2530472503","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530472503?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, April 28, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,today announced that an abstract has been accepted at the American Thoracic Society  2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.Details of the poster presentation are as follows:. Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides  in Three Dimensional  Alveolospheres from IPF and Normal Donor Lung Samples Poster #: P1463Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and FibrosisDate & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET. Rein Investor Relations & Media Contact:Argot Partnersrein@argotpartners.com 212-600-1902","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ATS","RNTX","BK4117","AFG","BK4007","BK4161","LENZ","CSD","BK4107"],"gpt_icon":0},{"id":"2530995847","title":"Celestica Announces First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2530995847","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530995847?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:15","pubTimestamp":1745525700,"startTime":"0","endTime":"0","summary":"Q1 2025 revenue and adjusted EPS* above the high end of our guidance ranges;Raising 2025 annual outlook. TORONTO, April 24, 2025  -- Celestica Inc.  , a leader in design, manufacturing, hardware platform and supply chain solutions for the world's most innovative companies, today announced financial results for the quarter ended March31, 2025 .Adjusted operating margin *: 7.1%, compared to 5.9% for Q1 2024.“Celestica delivered a strong first quarter in 2025, achieving revenue of $2.65 billion and non-GAAP adjusted EPS* of $1.20, both surpassing the high end of our guidance ranges. This strong performance was further highlighted by our highest ever adjusted operating margin* of 7.1%,” stated Rob Mionis, President and CEO.“With these results, and a strengthening demand outlook from our CCS customers, we are raising our full-year 2025 outlook. We now expect revenue to reach $10.85 billion, an increase from our prior $10.7 billion, and anticipate non-GAAP adjusted EPS* of $5.00, up from our","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celestica-announces-first-quarter-2025-201500873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2125910500.SGD","SBC","LU0029874061.USD","BK4126","LU0128526141.USD","LU2045819591.USD","CLS","BK4585","BK4088","CCS","TRS","BK4161","ATS","BK4588","BK4196","BK4145"],"gpt_icon":0},{"id":"2529874081","title":"United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874081","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874081?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:00","pubTimestamp":1745233200,"startTime":"0","endTime":"0","summary":"Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium. An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session. SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 21, 2025----United Therapeutics Corporation , a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society  International Conference in San Francisco on May 16-21, 2025.At ATS, United Therapeutics is sponsoring several events including the Respiratory Innovation Summit and the ATS Research Program Benefit Networking Event, and the company is hosting the Jenesis Innovative Research Awards Ceremony.Thematic poster session. Sunday, May 18, 11:30 a.m. to 1:15 p.m. PT: A48/P1624 – TETON Phase 3 Clinical Trials of Inhaled Treprosti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/united-therapeutics-feature-clinical-data-110000565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","LU1699723380.USD","BK4117","LU1571399168.USD","ATS","BK4532","PT","BK4139","UTHR","BK4161","BK4166","PBC","BK4107"],"gpt_icon":0},{"id":"2527211240","title":"GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2527211240","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527211240?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:35","pubTimestamp":1744806900,"startTime":"0","endTime":"0","summary":"LA JOLLA, CA, April 16, 2025  -- GRI Bio, Inc.  , a biotechnology company advancing an innovative pipeline of Natural Killer T  cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been selected for poster presentation in a poster discussion session at the 2025 ATS International Conference being held May 18-21, 2025 in San Francisco, CA.Details of the presentation are as follows:Title: Inactivation of iNKT Cells After the Inflammatory Phase Leads to Significant Inhibition of Fibroblast Activation and Fibrosis in a Model of Pulmonary FibrosisPoster Board Number: 810Presenter: Marc Hertz, PhD, Chief Executive Officer of GRI BioSession: D21 - IMMUNOLOGICAL INSIGHTS IN LUNG INFLAMMATION AND REPAIRDate and Time: Wednesday, May 21, 2025 from 8:15-10:15 AM PTLocation: Room 2022/2024 , Moscone CenterFor more information about the 2025 ATS International Conference, please visit the conference website, here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gri-bio-announces-abstract-selected-123500260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","AFG","ATS","BK4107","BK4117","GRI","BK4007"],"gpt_icon":0},{"id":"2527240854","title":"ICE Bonds Enhances MBS Trading With New RFQ Protocol on ICE TMC Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2527240854","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527240854?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:30","pubTimestamp":1744806600,"startTime":"0","endTime":"0","summary":"New RFQ Protocol provides enhanced liquidity, flexibility and efficiency for MBS trading. NEW YORK & ATLANTA, April 16, 2025----ICE Bonds, part of Intercontinental Exchange , a leading global provider of technology and data, today announced the launch of a new Request-for-Quote  protocol for Mortgage-Backed Securities . This new functionality sits alongside ICE Bonds’ existing MBS Click-to-Trade marketplace and allows clients to send MBS RFQs within ICE TMC’s anonymous trading pool.The ICE TMC platform now offers an enhanced suite of execution capabilities for MBS trading, providing wealth management and retail brokerage clients with a more flexible and efficient trading environment. This new RFQ feature complements the platform’s existing Click-to-Trade functionality, driving increased liquidity and execution efficiency in the MBS market.\"The addition of RFQ trading meaningfully enhances our MBS offering, expanding the ways our clients can access liquidity and engage with the market,\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ice-bonds-enhances-mbs-trading-123000800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4198","IE00BQXX3F31.USD","GB00BDT5M118.USD","LU2237957811.SGD","KIDS","LU0154236417.USD","BK4563","LU1974910355.USD","LU0390134368.USD","LU0417517546.SGD","MBS","BK4588","IE00BQXX3C00.GBP","SG9999004303.SGD","LU2106854487.HKD","LU0256863811.USD","LU1201861249.SGD","LU0256863902.USD","BK4585","LU2237957902.USD","ATS","LU2023250843.SGD","SGXZ23171101.USD","LU0154245756.USD","LU0124676726.USD","LU0011850046.USD","BK4112","BK4161","LU0154245673.USD","IE00BQXX3D17.EUR","LU0738911758.USD","BK4168","LU0980610538.SGD","LU0130102774.USD","LU0130517989.USD","LU0477156953.USD","LU2023250504.SGD","LU0689626769.HKD","LU0648001328.SGD","LU1153585028.USD","LU0661504455.SGD","LU1917777945.USD","ICE","LU0949170772.SGD"],"gpt_icon":1},{"id":"2527211792","title":"SkyWater Appoints Dr. Percy Gilbert as Senior Vice President of Engineering","url":"https://stock-news.laohu8.com/highlight/detail?id=2527211792","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527211792?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:05","pubTimestamp":1744801500,"startTime":"0","endTime":"0","summary":"Gilbert’s extensive technical expertise, proven track record of accomplishments and dedication to R&D underscore his proficiency in advanced semiconductor technologies. BLOOMINGTON, Minn., April 16, 2025----SkyWater Technology , the trusted technology realization partner, today announced the appointment of Dr. Percy V. Gilbert as senior vice president of engineering. Gilbert will report directly to President and COO John Sakamoto and will be responsible for leading and expanding SkyWater’s engineering organization, which is integral to the company’s ongoing strategic growth in Advanced Technology Services , platform solutions and Wafer Services .\"The appointment of Percy to lead our engineering team represents a significant milestone for SkyWater,\" said Sakamoto. \"His leadership and technical expertise will drive our innovative culture as we continue to scale our operations and enhance our engineering capabilities. We look forward to leveraging his vast experience in semiconductor tech","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skywater-appoints-dr-percy-gilbert-110500698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4141","BK4539","BK4161","BK4006","ATS","WS","SKYT"],"gpt_icon":0},{"id":"2527442089","title":"Press Release: Securitize Acquires MG Stover's Fund Administration Business to Become the Largest Digital Asset Fund Administrator","url":"https://stock-news.laohu8.com/highlight/detail?id=2527442089","media":"Dow Jones","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527442089?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:23","pubTimestamp":1744748580,"startTime":"0","endTime":"0","summary":"Securitize Fund Services now administers over $38 billion in assets across 715 funds. MIAMI, April 15, 2025 /PRNewswire/ -- Securitize, the leading platform for real-world asset tokenization, has announced the acquisition of MG Stover's Fund Administration business, the pioneering fund administration firm for digital assets. With this acquisition, Securitize's subsidiary, Securitize Fund Services , becomes the world's largest digital asset fund administrator.This acquisition significantly expands SFS, enhancing its ability to provide best-in-class fund administration, compliance, and reporting solutions to institutional-grade asset issuers and investors, while seamlessly integrating with Securitize's broader offerings, including a broker-dealer and digital transfer agent capabilities, tokenization platform, operator of an alternative trading system , and digital asset management.As of Monday April 14, 2025*, Securitize has issued $3.3B+ in assets on-chain, including:. Securitize, the l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4123","IE00B19Z4B17.USD","MG","IE00B7SZL793.SGD","ATS","IE00B66KJ199.SGD","BK4161","IE0031619046.USD"],"gpt_icon":0},{"id":"2527492058","title":"ParaZero Launches SafeAir M4 – Its Most Advanced Parachute Recovery System, Now Compatible with DJI Matrice 4","url":"https://stock-news.laohu8.com/highlight/detail?id=2527492058","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527492058?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:25","pubTimestamp":1744716300,"startTime":"0","endTime":"0","summary":"New generation of parachute technology combines a completely new design, swappable parachute capsules and triple sensor redundancy to redefine drone safety. TEL AVIV, Israel, April 15, 2025  -- ParaZero Technologies Ltd.  , an aerospace company focused on safety systems for commercial unmanned aerial systems and counter UAS systems, today announced the launch of its latest drone safety innovation – theSafeAir M4, its next-generation autonomous parachute recovery system now fully compatible with the DJI Matrice 4 series.The SafeAir M4 represents the most advanced version of ParaZero’s proven SafeAir system, incorporating aircraft-grade technology, a newly developed airbag-based deployment mechanism, plug-and-play design, and multi-layered compliance with both U.S. and European aviation regulations.“The launch of the SafeAir M4 marks a strategic milestone in ParaZero’s efforts to lead the global drone safety market,” added Boaz Shetzer, CEO of ParaZero. “As drone operations scale across ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/parazero-launches-safeair-m4-most-112500399.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AEIS","ATS","BK4603","BK4081","BK4157","IE00B66KJ199.SGD","PRZO","BK4161","IE0031619046.USD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","FTS","BK4532"],"gpt_icon":0},{"id":"2527140284","title":"ATS Corporation to Engage with Investors at RBC Capital Markets Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2527140284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527140284?lang=en_us&edition=fundamental","pubTime":"2025-04-15 05:39","pubTimestamp":1744666749,"startTime":"0","endTime":"0","summary":"ATS Corporation ( ($TSE:ATS) ) has provided an announcement. ATS Corporation announced that its Chief Financial Officer, Ryan McLeod, will particip...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ats-corporation-to-engage-with-investors-at-rbc-capital-markets-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ats-corporation-to-engage-with-investors-at-rbc-capital-markets-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","ATS","ISBC","BK4161","BK4207"],"gpt_icon":0},{"id":"2527169147","title":"ATS to Participate in the RBC Capital Markets Canadian Industrials Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2527169147","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527169147?lang=en_us&edition=fundamental","pubTime":"2025-04-15 05:01","pubTimestamp":1744664460,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Ontario, April 14, 2025----ATS Corporation   today announced that Ryan McLeod, Chief Financial Officer will participate in the RBC Capital Markets Canadian Industrials Conference in Toronto on May 15, 2025.Management will host institutional investor meetings at the Conference, which can be arranged by contacting your RBC Capital Markets representative or dgalison@atsautomation.com.For general media inquiries, contact: Matthew RobinsonDirector, Corporate Affairs & CommunicationATS Corporation730 Fountain Street NorthCambridge, ON, N3H 4R7 653-6500mrobinson@atsautomation.com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ats-participate-rbc-capital-markets-210100305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4207","BK4161","ATS"],"gpt_icon":0},{"id":"2526848299","title":"AI might be scanning your resume. Here’s what job hunters should know","url":"https://stock-news.laohu8.com/highlight/detail?id=2526848299","media":"CNN Business","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526848299?lang=en_us&edition=fundamental","pubTime":"2025-04-08 22:00","pubTimestamp":1744120838,"startTime":"0","endTime":"0","summary":"A human resources representative or hiring manager may not be the first to review your resume. Instead, it might be an AI-powered tool.With some job postings attracting hundreds or thousands of applications, companies are increasingly using AI to sort through applicants before they reach a human recruiter. According to data from jobseeker resource site Resume Genius, 48% of hiring managers report using AI to screen resumes and applications, and the AI recruitment sector is expected to experience a compound annual growth rate of 6.1% between 2023 and 2030, according to the Society for Human Resources Management.While companies have long been using applicant tracking systems  to parse resumes for skills and keywords, AI has the potential to further automate the process by “reading” resumes and applications to find suitable candidates.But can that make it more difficult to guarantee a resume gets seen by a human?Experts say AI can benefit both recruiters and candidates by allowing applica","market":"us","thumbnail":"https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1357880678.jpg?c=16x9&q=h_144,w_256,c_fill","type":0,"news_type":0,"thumbnails":["https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1357880678.jpg?c=16x9&q=h_144,w_256,c_fill"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://edition.cnn.com/2025/04/08/tech/ai-resume-job-hunters/index.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cnn_highlight","symbols":["ATS","BK4161"],"gpt_icon":0},{"id":"2525076694","title":"Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2525076694","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525076694?lang=en_us&edition=fundamental","pubTime":"2025-04-08 04:05","pubTimestamp":1744056300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April  07, 2025  (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 A","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3057198/0/en/Pliant-Therapeutics-Announces-Upcoming-Presentations-at-the-2025-American-Thoracic-Society-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4007","BK4107","BK4161","LENZ","BK4117","BK4139","ATS"],"gpt_icon":0},{"id":"2524923779","title":"Is Now An Opportune Moment To Examine ATS Corporation (TSE:ATS)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524923779","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524923779?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:41","pubTimestamp":1743676915,"startTime":"0","endTime":"0","summary":"ATS Corporation , might not be a large cap stock, but it received a lot of attention from a substantial price movement on the TSX over the last few months, increasing to CA$44.75 at one point, and dropping to the lows of CA$35.87. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether ATS' current trading price of CA$37.52 reflective of the actual value of the mid-cap?Or is it currently undervalued, providing us with the opportunity to buy?Let’s take a look at ATS’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/now-opportune-moment-examine-ats-104155715.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATS","TSE","BK4161","BK4090"],"gpt_icon":0},{"id":"2522724903","title":"Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2522724903","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522724903?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"- Data from the ASCENT study of LIQ861  in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life. - Case study highlights the long-term safety and tolerability of LIQ861  in a PAH patient transitioning from parenteral treprostinil in INSPIRE study. MORRISVILLE, N.C., March 27, 2025  -- Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease,today announced the company will present three posters at the AmericanThoracic Society  2025 International Conference, taking placeMay 18-21, 2025, inSan Francisco. Two posters will highlight new data from the company’s open-label ASCENT study of LIQ861  in PH-ILD patients with a focus on safety, tolerability, exploratory changes in 6-minute walk distance, quality of life, and changes in cardiac effort. A third poster is a case study of a patient with PAH participating in the open-label extension stu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/liquidia-announces-poster-presentations-american-120000468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4007","BK4161","BK4117","ATS","LQDA","BK4107"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":106,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-05","symbol":"ATS","fiscalQuarterEnding":"2024/12","expectedEps":0.23,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1738731600000,"reportTimeType":"pre","actualEps":0.23},{"market":"US","date":"2024-11-06","symbol":"ATS","fiscalQuarterEnding":"2024/09","expectedEps":0.25,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"pre","actualEps":0.18},{"market":"US","date":"2024-08-08","symbol":"ATS","fiscalQuarterEnding":"2024/06","expectedEps":0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":0.37},{"market":"US","date":"2024-05-16","symbol":"ATS","fiscalQuarterEnding":"2024/03","expectedEps":0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715832000000,"reportTimeType":"pre","actualEps":0.48},{"market":"US","date":"2024-02-07","symbol":"ATS","fiscalQuarterEnding":"2023/12","expectedEps":0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1707282000000,"reportTimeType":"pre","actualEps":0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.75,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1745985600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ATS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ATS","date":"2025-05-09","current":38.494248,"percent":0.699134,"low":18.278787,"twenty":22.972956,"median":33.554541,"eighty":42.647498,"high":49.784492,"avg":33.160264,"sd":8.812147,"marketCap":2471983722.75},"quantilePoints":[{"date":"2023-06-02","current":46.343344,"twenty":46.194425,"median":46.266425,"eighty":46.306886,"marketCap":4385290976.46},{"date":"2023-06-09","current":46.009827,"twenty":46.17581,"median":46.28258,"eighty":46.915752,"marketCap":4390539453.8},{"date":"2023-06-16","current":45.438012,"twenty":45.320112,"median":46.164952,"eighty":46.476751,"marketCap":4375388926.84},{"date":"2023-06-23","current":48.145057,"twenty":45.487654,"median":46.266425,"eighty":47.860268,"marketCap":4658766213.85},{"date":"2023-06-30","current":46.896248,"twenty":45.651659,"median":46.266425,"eighty":47.485058,"marketCap":4511580364.18},{"date":"2023-07-07","current":46.270844,"twenty":46.009827,"median":46.312962,"eighty":47.5378,"marketCap":4411747145.22},{"date":"2023-07-14","current":48.698172,"twenty":46.043025,"median":46.511353,"eighty":47.780498,"marketCap":4728914205.59},{"date":"2023-07-21","current":48.480908,"twenty":46.105078,"median":46.872979,"eighty":48.286922,"marketCap":4686318579.71},{"date":"2023-07-28","current":45.850462,"twenty":46.043025,"median":46.851428,"eighty":48.286922,"marketCap":4428020690.86},{"date":"2023-08-04","current":44.368411,"twenty":46.009827,"median":46.763285,"eighty":48.152813,"marketCap":4237745227.85},{"date":"2023-08-11","current":42.700705,"twenty":45.438012,"median":46.511353,"eighty":48.145057,"marketCap":4326916372.16},{"date":"2023-08-18","current":40.050115,"twenty":44.926078,"median":46.32649,"eighty":48.075247,"marketCap":4021626143.41},{"date":"2023-08-25","current":41.899702,"twenty":43.443089,"median":46.270844,"eighty":48.061899,"marketCap":4194356348.69},{"date":"2023-08-31","current":43.312379,"twenty":42.678859,"median":46.219245,"eighty":47.836778,"marketCap":4344740041.37},{"date":"2023-09-08","current":43.843953,"twenty":42.897314,"median":46.105078,"eighty":47.634879,"marketCap":4353234860.78},{"date":"2023-09-15","current":43.042951,"twenty":42.657014,"median":45.930144,"eighty":47.433983,"marketCap":4325894000.62},{"date":"2023-09-22","current":41.921548,"twenty":42.559437,"median":45.562117,"eighty":47.311701,"marketCap":4220969734.92},{"date":"2023-09-29","current":42.533222,"twenty":42.508464,"median":45.081733,"eighty":47.274981,"marketCap":4280367687.17},{"date":"2023-10-06","current":40.050115,"twenty":42.428364,"median":44.926078,"eighty":47.160162,"marketCap":3958860964.51},{"date":"2023-10-13","current":39.423877,"twenty":42.00893,"median":44.615828,"eighty":47.035061,"marketCap":3917634187.34},{"date":"2023-10-20","current":36.088795,"twenty":41.126371,"median":44.229891,"eighty":46.935301,"marketCap":3572025991.12},{"date":"2023-10-27","current":34.661554,"twenty":40.778231,"median":44.058847,"eighty":46.909266,"marketCap":3403618402.31},{"date":"2023-11-03","current":33.358105,"twenty":40.050115,"median":43.843953,"eighty":46.860392,"marketCap":3284508208.07},{"date":"2023-11-10","current":31.05346,"twenty":39.978754,"median":43.47968,"eighty":46.850053,"marketCap":3541182846.54},{"date":"2023-11-17","current":33.712074,"twenty":39.645245,"median":43.312379,"eighty":46.711431,"marketCap":3845894896.75},{"date":"2023-11-24","current":33.592349,"twenty":38.190334,"median":43.072078,"eighty":46.623309,"marketCap":3848769791.51},{"date":"2023-12-01","current":33.655362,"twenty":35.166914,"median":42.886392,"eighty":46.541855,"marketCap":3891785593.98},{"date":"2023-12-08","current":33.604952,"twenty":34.322082,"median":42.591477,"eighty":46.44537,"marketCap":3879525100.59},{"date":"2023-12-15","current":35.923838,"twenty":34.218738,"median":42.507736,"eighty":46.366559,"marketCap":4204253502},{"date":"2023-12-22","current":36.07507,"twenty":34.272496,"median":42.474968,"eighty":46.323119,"marketCap":4257700834.69},{"date":"2023-12-29","current":36.289315,"twenty":34.310293,"median":42.423994,"eighty":46.304224,"marketCap":4315633982.44},{"date":"2024-01-05","current":34.650971,"twenty":34.327977,"median":42.161849,"eighty":46.287991,"marketCap":4072504954.25},{"date":"2024-01-12","current":35.442932,"twenty":34.397952,"median":41.910625,"eighty":46.273191,"marketCap":4139113955.77},{"date":"2024-01-19","current":36.274955,"twenty":34.423844,"median":41.655761,"eighty":46.2585,"marketCap":4216951441.35},{"date":"2024-01-26","current":36.917882,"twenty":34.562753,"median":40.778299,"eighty":46.231655,"marketCap":4292072985.19},{"date":"2024-02-02","current":36.987217,"twenty":34.654752,"median":40.235802,"eighty":46.154093,"marketCap":4330447033.68},{"date":"2024-02-09","current":31.2472,"twenty":34.423844,"median":40.050115,"eighty":46.10731,"marketCap":4053209917.9},{"date":"2024-02-16","current":29.911027,"twenty":34.218738,"median":40.010065,"eighty":46.067846,"marketCap":3869003534.07},{"date":"2024-02-23","current":28.569192,"twenty":34.062459,"median":39.908119,"eighty":46.029746,"marketCap":3697982548.6},{"date":"2024-03-01","current":28.954191,"twenty":33.729718,"median":39.700587,"eighty":45.946081,"marketCap":3727658474.68},{"date":"2024-03-08","current":28.897573,"twenty":33.622723,"median":38.630157,"eighty":45.760452,"marketCap":3749905081.21},{"date":"2024-03-15","current":28.33706,"twenty":33.535637,"median":37.535596,"eighty":45.60011,"marketCap":3663186667.6},{"date":"2024-03-22","current":28.378306,"twenty":33.360741,"median":37.125888,"eighty":45.512475,"marketCap":3664397837.7},{"date":"2024-03-28","current":27.463826,"twenty":33.187804,"median":36.956482,"eighty":45.379062,"marketCap":3545999564.77},{"date":"2024-04-05","current":25.261057,"twenty":31.829239,"median":36.880063,"eighty":45.11865,"marketCap":3270651387.12},{"date":"2024-04-12","current":24.173756,"twenty":30.404732,"median":36.432536,"eighty":45.004481,"marketCap":3078077137.88},{"date":"2024-04-19","current":24.609778,"twenty":29.677763,"median":36.289315,"eighty":44.938488,"marketCap":3127556802.58},{"date":"2024-04-26","current":25.396884,"twenty":29.011941,"median":36.169269,"eighty":44.868397,"marketCap":3239367008.29},{"date":"2024-05-03","current":25.125077,"twenty":28.84322,"median":36.062467,"eighty":44.633305,"marketCap":3203669221.23},{"date":"2024-05-10","current":26.025435,"twenty":28.633736,"median":35.997283,"eighty":44.566345,"marketCap":3323128791.91},{"date":"2024-05-17","current":23.786609,"twenty":28.457413,"median":35.841921,"eighty":44.342163,"marketCap":3384597470.53},{"date":"2024-05-24","current":21.936652,"twenty":28.195987,"median":35.701363,"eighty":44.23426,"marketCap":3102092113.2},{"date":"2024-05-31","current":21.435159,"twenty":27.970637,"median":35.598334,"eighty":44.222609,"marketCap":3039383806.02},{"date":"2024-06-07","current":22.690097,"twenty":27.463826,"median":35.382456,"eighty":43.895086,"marketCap":3211638521.11},{"date":"2024-06-14","current":22.285278,"twenty":26.048085,"median":35.173981,"eighty":43.895086,"marketCap":3139567043.35},{"date":"2024-06-21","current":21.323834,"twenty":25.875989,"median":34.8436,"eighty":43.864406,"marketCap":3015344623.92},{"date":"2024-06-28","current":22.482628,"twenty":25.849972,"median":34.751792,"eighty":43.843953,"marketCap":3180274284.27},{"date":"2024-07-05","current":21.972427,"twenty":25.639244,"median":34.657272,"eighty":43.651713,"marketCap":3127376247.29},{"date":"2024-07-12","current":22.998515,"twenty":25.494281,"median":34.422199,"eighty":43.533747,"marketCap":3270585876.4},{"date":"2024-07-15","current":22.953023,"twenty":25.430859,"median":34.413972,"eighty":43.516271,"marketCap":3254489261.98},{"date":"2024-08-02","current":20.309458,"twenty":25.403679,"median":34.373922,"eighty":43.501635,"marketCap":2841766295.19},{"date":"2024-08-09","current":20.723514,"twenty":25.129607,"median":34.224644,"eighty":43.440249,"marketCap":2735666122.5},{"date":"2024-08-16","current":19.860035,"twenty":24.796645,"median":34.162619,"eighty":43.405587,"marketCap":2630022203.9},{"date":"2024-08-23","current":19.838448,"twenty":24.268888,"median":33.920018,"eighty":43.283252,"marketCap":2645505418.49},{"date":"2024-08-30","current":19.471469,"twenty":23.8321,"median":33.734128,"eighty":43.147809,"marketCap":2621186477.04},{"date":"2024-09-06","current":18.602592,"twenty":23.494241,"median":33.671115,"eighty":43.072078,"marketCap":2495925620.93},{"date":"2024-09-13","current":19.185441,"twenty":22.907687,"median":33.604952,"eighty":43.042951,"marketCap":2560815499.76},{"date":"2024-09-20","current":20.831449,"twenty":22.803751,"median":33.570295,"eighty":43.028387,"marketCap":2786196948.41},{"date":"2024-09-27","current":21.948725,"twenty":22.594145,"median":33.45372,"eighty":42.744396,"marketCap":2956487278.6},{"date":"2024-10-04","current":21.646505,"twenty":22.472834,"median":33.3614,"eighty":42.700705,"marketCap":2900362552.24},{"date":"2024-10-11","current":21.560157,"twenty":22.285278,"median":33.233174,"eighty":42.591477,"marketCap":2843647655.11},{"date":"2024-10-18","current":22.617927,"twenty":22.261739,"median":32.698187,"eighty":42.533222,"marketCap":2977792893.11},{"date":"2024-10-25","current":22.645897,"twenty":22.285278,"median":31.73976,"eighty":42.511377,"marketCap":2967565955.08},{"date":"2024-10-31","current":23.088453,"twenty":22.329808,"median":31.05346,"eighty":42.505551,"marketCap":3006452868.32},{"date":"2024-11-08","current":30.478219,"twenty":22.389519,"median":30.568298,"eighty":42.486619,"marketCap":2853731574.85},{"date":"2024-11-15","current":30.530988,"twenty":22.401664,"median":30.478219,"eighty":42.476424,"marketCap":2830133907.78},{"date":"2024-11-22","current":30.757144,"twenty":22.402758,"median":30.568681,"eighty":42.451666,"marketCap":2862659955.58},{"date":"2024-11-29","current":33.961013,"twenty":22.434826,"median":30.673837,"eighty":42.419625,"marketCap":3148783777.17},{"date":"2024-12-06","current":34.669633,"twenty":22.46611,"median":30.907914,"eighty":42.257969,"marketCap":3210086264.85},{"date":"2024-12-13","current":33.207161,"twenty":22.47871,"median":31.108842,"eighty":42.148741,"marketCap":3040755582.89},{"date":"2024-12-20","current":31.48838,"twenty":22.488641,"median":31.48838,"eighty":42.00893,"marketCap":2849502272.41},{"date":"2024-12-27","current":33.734858,"twenty":22.494713,"median":31.970845,"eighty":41.91281,"marketCap":3041459063.87},{"date":"2025-01-03","current":33.410701,"twenty":22.507997,"median":32.326091,"eighty":41.867662,"marketCap":3006099952.21},{"date":"2025-01-10","current":30.583758,"twenty":22.548751,"median":32.187154,"eighty":41.739502,"marketCap":2758779888.76},{"date":"2025-01-17","current":28.714206,"twenty":22.594145,"median":31.76484,"eighty":41.57202,"marketCap":2591110278.91},{"date":"2025-01-24","current":30.922991,"twenty":22.613171,"median":31.446918,"eighty":40.977822,"marketCap":2794075415.08},{"date":"2025-01-31","current":29.754521,"twenty":22.627085,"median":31.164224,"eighty":40.788494,"marketCap":2682414705.78},{"date":"2025-02-07","current":44.52783,"twenty":22.642592,"median":31.108842,"eighty":40.977822,"marketCap":2778433490.84},{"date":"2025-02-14","current":46.096561,"twenty":22.681257,"median":31.405456,"eighty":41.965239,"marketCap":2894690862.79},{"date":"2025-02-21","current":45.29574,"twenty":22.741461,"median":31.73976,"eighty":42.419625,"marketCap":2847627453.27},{"date":"2025-02-28","current":46.79865,"twenty":22.792532,"median":32.079,"eighty":42.507008,"marketCap":2895255396.7},{"date":"2025-03-07","current":41.862084,"twenty":22.806185,"median":32.332694,"eighty":42.635168,"marketCap":2622361985.36},{"date":"2025-03-14","current":41.423278,"twenty":22.822194,"median":32.713389,"eighty":42.635168,"marketCap":2565848922.04},{"date":"2025-03-21","current":43.880591,"twenty":22.853037,"median":32.981006,"eighty":43.034213,"marketCap":2732813300.12},{"date":"2025-03-28","current":42.224099,"twenty":22.88278,"median":33.123373,"eighty":43.054602,"marketCap":2633489494.72},{"date":"2025-04-04","current":39.042756,"twenty":22.901877,"median":33.222238,"eighty":43.034213,"marketCap":2482102274.67},{"date":"2025-04-11","current":36.168577,"twenty":22.907687,"median":33.258379,"eighty":42.953904,"marketCap":2303349084},{"date":"2025-04-17","current":36.662234,"twenty":22.91307,"median":33.3614,"eighty":42.840307,"marketCap":2360722684.91},{"date":"2025-04-25","current":38.011562,"twenty":22.933896,"median":33.415912,"eighty":42.72692,"marketCap":2443342344.25},{"date":"2025-05-02","current":38.318726,"twenty":22.957542,"median":33.501164,"eighty":42.694361,"marketCap":2471450690},{"date":"2025-05-09","current":38.494248,"twenty":22.972956,"median":33.554541,"eighty":42.647498,"marketCap":2471983722.75}],"updateTime":1747003238582}}}